These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23313657)

  • 1. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine.
    Tavares F; Cheuvart B; Heineman T; Arellano F; Dubin G
    Vaccine; 2013 Mar; 31(13):1759-64. PubMed ID: 23313657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.
    Leroux-Roels G; Clément F; Vandepapelière P; Fourneau M; Heineman TC; Dubin G
    Hum Vaccin Immunother; 2013 Jun; 9(6):1254-62. PubMed ID: 23434737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
    Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
    N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
    ; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
    Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.
    Verstraeten T; Descamps D; David MP; Zahaf T; Hardt K; Izurieta P; Dubin G; Breuer T
    Vaccine; 2008 Dec; 26(51):6630-8. PubMed ID: 18845199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
    Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
    Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein D adjuvant herpes simplex virus vaccine.
    Bernstein D
    Expert Rev Vaccines; 2005 Oct; 4(5):615-27. PubMed ID: 16221064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.
    Baril L; Rosillon D; Willame C; Angelo MG; Zima J; van den Bosch JH; Van Staa T; Boggon R; Bunge EM; Hernandez-Diaz S; Chambers CD
    Vaccine; 2015 Nov; 33(48):6884-91. PubMed ID: 26206268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
    Awasthi S; Shaw C; Friedman H
    Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of herpes genitalis by the 'Bulgarian' vaccine F.HSV-2V(PRK): preliminary clinical evidence.
    Skinner GR; Davies JA; Dundarov S; Andonov P
    Croat Med J; 2000 Dec; 41(4):378-83. PubMed ID: 11063759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety evaluation of adjuvants during vaccine development: the AS04 experience.
    Garçon N; Segal L; Tavares F; Van Mechelen M
    Vaccine; 2011 Jun; 29(27):4453-9. PubMed ID: 21527299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
    de Bruyn G; Vargas-Cortez M; Warren T; Tyring SK; Fife KH; Lalezari J; Brady RC; Shahmanesh M; Kinghorn G; Beutner KR; Patel R; Drehobl MA; Horner P; Kurtz TO; McDermott S; Wald A; Corey L
    Vaccine; 2006 Feb; 24(7):914-20. PubMed ID: 16213066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy results of a trial of a herpes simplex vaccine.
    Belshe RB; Leone PA; Bernstein DI; Wald A; Levin MJ; Stapleton JT; Gorfinkel I; Morrow RL; Ewell MG; Stokes-Riner A; Dubin G; Heineman TC; Schulte JM; Deal CD;
    N Engl J Med; 2012 Jan; 366(1):34-43. PubMed ID: 22216840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of prophylactic vaccines for genital and neonatal herpes.
    Jones CA; Cunningham AL
    Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and prospects for development of an HSV vaccine.
    Johnston C; Koelle DM; Wald A
    Vaccine; 2014 Mar; 32(14):1553-60. PubMed ID: 24016811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons.
    Wald A; Koelle DM; Fife K; Warren T; Leclair K; Chicz RM; Monks S; Levey DL; Musselli C; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8520-9. PubMed ID: 21945262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.